Why Did Novartis Pay Trump’s Lawyer $1.2 Million? Look At Its Drug Prices
Promises to control pharma prices threaten profits for Switzerland-based Novartis, which sells some of the costliest drugs in the world.
Drug Costs
521-540 of 706 results
-
-
Podcast: KHN’s ‘What The Health?’ The Politics Of Rising Premiums And Menu Labeling
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Margot Sanger-Katz of The New York Times and Anna Edney of Bloomberg News discuss the latest on the politics of rising premiums, GOP efforts to take back money from the Children’s Health Insurance Program, and the controversy over new rules requiring calorie information on menus. Plus for extra credit, the panelists recommend their favorite health stories of the week.
-
Midterm Elections Are Shaping Up To Be A Referendum On Trumpism
Even voters who say they are more enthusiastic about voting in this congressional election than in past ones are not motivated by any specific issue. But, according to a poll out Thursday, health care policies rank high among topics voters want candidates to address.
By Rachel Bluth -
Medicare Beneficiaries Feel The Pinch When They Can’t Use Drug Coupons
Federal law prohibits them from using the coupons drugmakers offer to help patients cover their share of a medicine’s cost.
-
‘Pharma Bro’ Shkreli Is In Prison, But Daraprim’s Price Is Still High
The saga of Martin Shkreli and Turing Pharmaceuticals focused a lot of attention on prescription drug prices, but no reversal of the exponential price increases for the lifesaving drug Daraprim resulted. The story offers an object lesson into the interworkings of the pharmaceutical market.
-
How A Drug Company Under Pressure For High Prices Ratchets Up Political Activity
Denmark-based drugmaker Novo Nordisk has invested more in lobbying and doubled political donations since 2015.
By Jay Hancock and Elizabeth Lucas -
Best Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes, who reads everything on health care to compile our daily Morning Briefing, offers the best and most provocative stories for the weekend.
-
Dissecting The Rhetoric Vs. Reality Of Trump’s Tough Talk On Drug Prices
President Donald Trump’s upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.
-
Must-Reads Of The Week From Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
-
Podcast: KHN’s ‘What The Health?’ Nothing In Health Care Ever Goes Away
In this episode of KHN’s “What the Health?” Sarah Jane Tribble of Kaiser Health News, Joanne Kenen of Politico, Margot Sanger-Katz of The New York Times and Paige Winfield Cunningham of The Washington Post examine how even after Republicans failed to repeal and replace the Affordable Care Act, the health care debate continues to roil politics. They discuss how Republicans in Congress have shifted their ACA messaging and how the Democrats are looking to Medicare expansion. They also discuss state efforts to expand Medicaid and drug pricing. And they spend a moment talking about Congress’ push to do something about the opioid crisis.
-
Nation’s Top Doc Wants The Overdose Antidote Widely On Hand. Is That Feasible?
Surgeon General Jerome Adams urged more people to carry the drug naloxone, a lifesaving treatment for opioid overdoses. But this policy is tricky to implement.
By Shefali Luthra and Rachel Bluth -
Drug Test Spurs Frank Talk Between Hypertension Patients And Doctors
Roughly half of patients don't take their high blood pressure medicine as they should, even though heart disease is the leading cause of death in America. Now, a drug test can flag whether a patient is taking the prescribed medication and is meant to spark a more truthful conversation between patient and doctor.
-
Federal Appeals Court Puts Chill On Maryland Law To Fight Drug Price-Gouging
The decision in Maryland’s case could slow momentum for other states that are attempting to take action to curb high drug costs.
-
Great Weekend Reads From KHN
KHN's newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don't have to.
-
How A Drugmaker Turned The Abortion Pill Into A Rare-Disease Profit Machine
An abortion drug invented decades ago is being used to treat Cushing’s syndrome — and it’s bringing in tens of millions of dollars a year.
-
C-SPAN: FDA Commissioner Scott Gottlieb Talks To KHN
Kaiser Health News reporter Sarah Jane Tribble sat down with Food and Drug Administration Commissioner Scott Gottlieb on C-SPAN’s "Newsmakers" program. The conversation ranged from how the nation should combat the opioid epidemic to reining in drug prices.
-
-
Podcast: KHN’s ‘What The Health?’ VA Secretary Out, Privatization In?
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Sarah Kliff of Vox.com, Anna Edney of Bloomberg News and Alice Ollstein of Talking Points Memo discuss President Donald Trump’s firing of David Shulkin, the secretary of Veterans Affairs, and Shulkin’s claim that he was forced out by those who want to privatize VA health care.
-
Readers Seek Transparency On Surgery Centers, ‘Bill Of The Month’ Investigations
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
-
Podcast: KHN’s ‘What The Health?’ Health Law Fix Misses The Spending Bill Train
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Margot Sanger-Katz of The New York Times discuss the apparent demise of bipartisan legislation aimed at shoring up parts of the Affordable Care Act. They also discuss aggressive new efforts by the Food and Drug Administration to regulate tobacco products. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.